secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0000950170-25-110370
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum launches ORLYNVAH, first oral penem antibiotic in U.S., for uUTI
-----------------------------------------------------------------------

- FDA approved ORLYNVAH in Oct 2024; commercial launch announced Aug 20, 2025.
- First oral penem antibiotic in U.S.; first new branded uUTI product in >25 years.
- 57% of initial uUTIs resistant to at least one antibiotic class per 2024 study.
- Copay savings program allows eligible patients to get ORLYNVAH for as low as $25.
- CEO cites urgent need for new oral therapies amid rising antibiotic resistance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025110370/0000950170-25-110370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025110370/itrm-20250820.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-110370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer